Safety and Efficacy Study of DCVax-Direct in Solid Tumors

Status unconfirmed · Phase 1/Phase 2

Conditions studied: Locally Advanced Tumor, Metastatic Solid Tissue Tumors, Liver Cancer, Colorectal Cancer, Pancreatic Cancer, Melanoma

In brief

The study comprises a Phase I component during which the optimal dose of DCVax-Direct for the treatment of solid tissue tumors will be identified, followed by a Phase II component to determine if the injection of DCVax-Direct into selected solid tissue tumors has the ability to reduce tumor growth.

Key facts

Study ID

NCT01882946

Run by

Northwest Biotherapeutics

People needed

60

Starts

2013-06-01

Last updated by the study team

2015-10-07

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Orlando Health — Orlando, Florida, United States
• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.